Gufic Biosciences bags CDSCO approval to manufacture drug for severe fungal infections
Isavuconazole for Injection 200 mg/vial is indicated for the treatment of patients who are 18 years of age and above.
New Delhi: Gufic Biosciences on Monday said it has received an approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market a drug used to treat invasive Aspergillosis and Mucormycosis.
The company has received approval for the production, sale and distribution of Isavuconazonium Sulfate API and finished formulation Isavuconazole for Injection 200 mg/vial, the company said in a statement.
Read also: Dr. Reddy's gets CDSCO panel nod to study Fosravuconazole L Lysine Ethanolate Capsule
Gufic group has been in the Pharmaceutical industry since 1970. The group is one of the largest manufacturers of Lyophilized injections in India and have a fully automated lyophilization plant. Its lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments. Gufic products are supplied to most hospital chains and medical facilities.
Read also: Novo Nordisk bags CDSCO panel nod to study anti neoplastic drug Concizumab
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.